Details for Patent: 9,095,509

Which drugs does patent 9,095,509 protect, and when does it expire?

Patent 9,095,509 protects RENVELA and is included in one NDA.

This patent has thirty-one patent family members in eighteen countries.

Summary for Patent: 9,095,509

Title:	Sachet formulation for amine polymers
Abstract:	A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
Inventor(s):	Bhagat; Hitesh R. (Wayland, MA), Goldberg; Jeffrey M. (Framingham, MA)
Assignee:	Genzyme Corporation (Cambridge, MA)
Application Number:	11/519,982
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,095,509

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	AB	RX	Yes	Yes			Y
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009	AB	RX	Yes	No			Y

International Family Members for US Patent 9,095,509

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006292672
Brazil	PI0616078
Canada	2622693
China	101272762
China	103027896